• Company Information
  • Product Pipeline
  • Investor Relations
  • Press Room
  • Careers
  • Contact

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs in the areas of infection, cancer and respiratory disease. The Company’s lead product candidate, cethromycin, is a novel once-a-day antibiotic developed for the treatment of respiratory tract infections. The Company has three product candidates that are either in clinical development or approved to begin clinical development, as well as six additional candidates in preclinical development.

Media Fact SheetCompany Fact Sheet

Press Room

Date Title
06/23/09 Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study
06/02/09 Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)
05/29/09 Advanced Life Sciences Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Restanza(TM) (cethromycin)

About Cethromycin

Cethromycin, Advanced Life Sciences’ lead product candidate, is a novel once-a-day antibiotic that recently demonstrated positive phase III results for the treatment of community acquired pneumonia (CAP). Cethromycin has a mechanism of action that may slow the onset of future bacterial resistance.

   
 
  • Home
  • Contact
  • Site Map
© 2008 Advanced Life Sciences Inc.   Terms of Use